Nkarta, Inc.

NASDAQ:NKTX

Biotechnology

Healthcare
$1.15 +3.41%

+$0.09 today

Market cap
$82.37M
Beta
0.90
P/E (TTM)
-2.0
EPS (TTM)
-$1.35
52W Low $1.63High $3.65

Volume 0.81M

Average 0.75M

NKTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Nkarta, Inc.NASDAQ: NKTX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 74.26M shares rose 0.5% year over year, in line with the +0.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +0.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
74.26M+0.3% QoQ
Last fiscal yearDec 2025
73.99M+9.0% YoY
LTMMar 2026
74.08M+0.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.5%——
1 year+9.0%——
3-year CAGR+19.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
73.99M USD
Year-over-year change
+9.0%
4-year CAGR
+22.5%

Weighted Avg Shares vs competitors

How NKTX compares with its peers on the latest reported figures

  • NKTX's LTM Mar 2026 weighted avg shares of 74.08M shares is the 4th highest of the 8 companies compared; the peer median is 44.2M shares.
  • Its year-over-year change of +0.6% is the lowest of 8, against a peer median of +32.5%.
  • Over three fiscal years its annual growth of +19.3% compares with a peer median of +39.2%.
NKTX Competitors Peer median
Weighted Avg Shares for NKTX and competitors
Company Period LTM YoY 3-year CAGR
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
FBRXForte Biosciences, Inc.LTM Mar 202688.77M +1552.7%+496.0%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
VORVor Biopharma Inc.LTM Mar 20265.81M +40.8%+70.9%
Peer median (excluding NKTX) 44.2M+32.5%+39.2%

Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue005.87M09.19M
Gross Profit00(5.87M)0(9.19M)
Gross Margin—————
Research & Development63.41M90.9M90.9M96.74M90.43M
Selling, General & Admin23.02M28.06M34.88M31.45M31.57M
Operating Expenses86.43M118.96M125.78M128.19M112.01M
Depreciation & Amortization1.76M2.64M5.87M9.15M9.19M
EBITDA(84.32M)(105.61M)(120.48M)(99.64M)(94.89M)
EBITDA Margin—————
Operating Income(86.43M)(118.96M)(131.65M)(128.19M)(121.21M)
Operating Margin—————
Interest Income370K5.59M14.11M19.32M15.49M
Interest Expense05.59M000
Other Income / Expenses354K5.12M14.15M19.4M17.12M
Income Before Tax(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(86.08M)(113.84M)(117.5M)(108.79M)(104.08M)
Net Margin—————
EPS (Basic)(2.62)(2.61)(2.40)(1.60)(1.41)
EPS (Diluted)(2.62)(2.61)(2.40)(1.60)(1.41)
Weighted Avg Shares32.86M43.63M49.01M67.87M73.99M
Weighted Avg Shares (Diluted)32.86M43.63M49.01M67.87M73.99M

Nkarta, Inc.

NASDAQ:NKTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.